Livagen – A Peptide Bioregulator of the Liver, GI Tract, and the Immune System

Livagen is a peptide bioregulator of the liver, GI tract, and immune system. Livagen peptide is almost identical to Epitalon—a peptide—telomerase activator and an anti-aging drug known for its effects on the immune system.

Livagen peptide acts on the DNA and gene expression patterns. The gene-activating effect of Livagen on the immune system and GI tract is due to its anti-aging features. This is inactive due to age-induced DNA condensation.^[1]

The Medical Benefits of Livagen peptide

Scientific studies have proven that Livagen has medical benefits for the human body which are:

1. How Livagen Peptide Modulates Chromatin and Immune System Function: The human body contains the nucleus that houses eukaryotes. Due to DNA packing, DNA in eukaryotes reduces to roughly 100,000. DNA is a double helix protein wrapped by histone proteins, which combine to form chromatin structures. The chromatin structure subsequently condenses to form chromosomes.

This pattern of organization has medical implications and supports several functions, including cell division and genetic material condensation for replication. This is to allow for cell fit and gene expression control.^[2] Researchers report that “Livagen causes de-heterochromatinization (activation) of chromatin, which is realized via modification of heterochromatin and heterochromatinized regions in chromosomes from old people.”

Livagen stimulates chromatin decondensation in the elderly by activating multiple genes in their lymphocytes, according to research. This mechanism promotes the activation of silent genes, such as ribosomal genes, which boost protein synthesis and cell activity.^[3]

• During the investigation, a comparison of Livagen, Epithalon, and Vilon was made. Livagen peptide has four impacts on lymphocytes, according to the results. Unpacking chromatin is one among them.
• Then there is decondensation.
• The third step is reactivating ribosomal genes to activate synthetic processes.
• And finally, the changing the expression of genes can occur.

B cells, T cells, and natural killer cells are all types of lymphocytes. T cells produce antibodies specific to cells infected with viruses, bacteria, or malignant cells, whereas B cells produce antiviral and antibacterial antibodies. T cells produce cytokines that influence immune responses and inflammation. The ability to manage B and T lymphocytes may benefit the prevention of infection and cancer.

2. How Livagen Influences Pain: Enkephalins are peptides that control nociception in the body. They attach to mu and delta-opioid receptors and can transmit pain signals. When Mu receptors, which bind to morphine, are triggered, they can lower pain, blood pressure, and awareness. Delta receptors can alleviate pain and may be involved in opiate-induced respiratory depression.^[4]

According to Livagen research, the peptide blocks enkephalin-degrading enzyme activity in the blood, causing a rise in natural painkiller levels. Scientists think Livagen peptide has the potential to be an effective pain reliever.

Livagen peptide’s pain effectiveness, side effects, and addictive potential alongside opioids such as Oxycontin are all undergoing research.

3. The Role of Livagen in the Heart: According to research, chromatin dysregulation is one of the pathogenic components of individuals with hypertrophic cardiomyopathy (HCM) and atherosclerosis.^[5] The scientists reported that “The peptide bioregulator Livagen could induce reactivation (deheterochromatinization) of chromatin to modify heterochromatinized chromosomal regions in cultured lymphocytes of aged individuals.”

Scientists believe that genes produced by chromatin decondensation in lymphocytes can minimize the long-term consequences of several forms of heart disease. Livagen peptide performs this function. In HCM patients, altered lymphocyte gene expression can minimize scarring and inflammation. Livagen peptide can also reduce the occurrence of HCM in genetically susceptible patients after a cardiac injury or heart attack.^[6]

Scientists think Livagen peptide will enable more advanced methods of reducing morbidity and death associated with cardiac illnesses.

4. Livagen Effect on the GI Tract: According to the Livagen study, the peptide can increase GI tract vagal nerve signaling and change levels of prostaglandins and mucosal nitric oxide. This can lead to gastroprotection, effectively managing diarrhea, symptoms, and inflammatory bowel disease.^[7]

DNA is expressed in a certain way for reasons favorable to health. However, chromosomal abnormalities worsen with age. These anomalies are caused by chromatin increasing condensation and decreased repair mechanisms. However, research shows condensation reversal may be essential for a prolonged lifetime. Livagen peptide is known to affect the process of DNA decondensation. This can aid in the prevention of various aging-related dysfunctions. Particularly those associated with decreased protein synthesis and immunological dysregulation.

Conclusion

Livagen is a peptide bioregulator of the liver, GI tract, and immune system. Livagen is almost identical to Epitalon—a peptide—telomerase activator and an anti-aging drug known for its effects on the immune system. Livagen provides several health advantages, including modification of chromatin and immune system function, pain relief, heart protection, and GI tract protection, as well as slowing aging and prolonging lifetime.

Livagen peptide, however, has minimal side effects.

It is vital to note that Livagen is a research peptide/chemical limited to educational and scientific purposes only, not for human use or consumption.

References

1. Lezhava T. A. (2001). Funktsional’nye osobennosti khromosom cheloveka i starenie [Human chromosome functional characteristics and aging]. Advances in gerontology = Uspekhi gerontologii, 8, 34–43.
2. Khavinson, V. K.h, Lezhava, T. A., Monaselidze, J. G., Dzhokhadze, T. A., Dvalishvili, N. A., Bablishvili, N. K., & Ryadnova, I. Y. (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of experimental biology and medicine, 134(4), 389–392. doi: 10.1023/a:1021924702103.
3. Lezhava, T., Monaselidze, J., Kadotani, T., Dvalishvili, N., & Buadze, T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian medical news, (133), 111–115.
4. Kost, N. V., Sokolov, O. I.u, Gabaeva, M. V., Zolotarev, I.uA., Malinin, V. V., & Khavinson, V. K.h (2003). Vliianie novykh peptidnykh bioreguliatorov livagena i épitalona na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum]. Izvestiia Akademii nauk. Seriia biologicheskaia, (4), 427–429.
5. Lezhava, T., Monaselidze, J., Kadotani, T., Dvalishvili, N., & Buadze, T. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian medical news, (133), 111–115.
6. Dzhokhadze, T. A., Buadze, T. Z.h, Gaĭozishvili, M. N., Rogava, M. A., & Lazhava, T. A. (2013). Georgian medical news, (225), 94–97.
7. Gyires, K., & Rónai, A. Z. (2001). Supraspinal delta- and mu-opioid receptors mediate gastric mucosal protection in the rat. The Journal of pharmacology and experimental therapeutics, 297(3), 1010–1015.

Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.